NO. Global vaccine market timelines for non-pandemic threats like Hantavirus extend beyond typical 3-year regulatory sprints. Despite localized ENSO-driven zoonotic spillover risk, current Phase 3 trial data is absent. 90% NO — invalid if major Big Pharma announces late-stage trials by 2024.
NO. Global vaccine market timelines for non-pandemic threats like Hantavirus extend beyond typical 3-year regulatory sprints. Despite localized ENSO-driven zoonotic spillover risk, current Phase 3 trial data is absent. 90% NO — invalid if major Big Pharma announces late-stage trials by 2024.
